3-hydroxyanthranilic acid has been researched along with Atherogenesis in 6 studies
3-Hydroxyanthranilic Acid: An oxidation product of tryptophan metabolism. It may be a free radical scavenger and a carcinogen.
3-hydroxyanthranilic acid : An aminobenzoic acid that is benzoic acid substituted at C-2 by an amine group and at C-3 by a hydroxy group. It is an intermediate in the metabolism of the amino acid tryptophan.
3-hydroxyanthranilate : A hydroxybenzoate that is the conjugate base of 3-hydroxyanthranilic acid.
| Excerpt | Relevance | Reference |
|---|---|---|
| "3-Hydroxyanthranilic acid inhibits atherosclerosis by regulating lipid metabolism and inflammation, two major components of this disease." | 7.78 | The tryptophan metabolite 3-hydroxyanthranilic acid lowers plasma lipids and decreases atherosclerosis in hypercholesterolaemic mice. ( Berg, M; Hansson, GK; Jönsson, A; Ketelhuth, DF; Lundberg, AM; Ovchinnikova, O; Zhang, L, 2012) |
| "3-Hydroxyanthranilic acid inhibits atherosclerosis by regulating lipid metabolism and inflammation, two major components of this disease." | 3.78 | The tryptophan metabolite 3-hydroxyanthranilic acid lowers plasma lipids and decreases atherosclerosis in hypercholesterolaemic mice. ( Berg, M; Hansson, GK; Jönsson, A; Ketelhuth, DF; Lundberg, AM; Ovchinnikova, O; Zhang, L, 2012) |
| "CC-chemokines and kynurenine pathway (KP) metabolites are associated with accelerated atherosclerosis in chronic kidney disease (CKD) patients." | 3.76 | 3-hydroxyanthranilic acid is independently associated with monocyte chemoattractant protein-1 (CCL2) and macrophage inflammatory protein-1beta (CCL4) in patients with chronic kidney disease. ( Kowalewska, A; Mysliwiec, M; Pawlak, D; Pawlak, K, 2010) |
| "Atherosclerosis is a chronic inflammatory disease involving immunological and metabolic processes." | 1.56 | 3-Hydroxyanthralinic acid metabolism controls the hepatic SREBP/lipoprotein axis, inhibits inflammasome activation in macrophages, and decreases atherosclerosis in Ldlr-/- mice. ( Agardh, H; Baumgartner, R; Berg, M; Bottcher, G; Forteza, MJ; Gisterå, A; Hansson, GK; Hurt-Camejo, E; Kareinen, I; Ketelhuth, DFJ; Polyzos, KA, 2020) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 2 (33.33) | 29.6817 |
| 2010's | 3 (50.00) | 24.3611 |
| 2020's | 1 (16.67) | 2.80 |
| Authors | Studies |
|---|---|
| Berg, M | 2 |
| Polyzos, KA | 1 |
| Agardh, H | 1 |
| Baumgartner, R | 1 |
| Forteza, MJ | 1 |
| Kareinen, I | 1 |
| Gisterå, A | 1 |
| Bottcher, G | 1 |
| Hurt-Camejo, E | 1 |
| Hansson, GK | 2 |
| Ketelhuth, DFJ | 1 |
| Gerdes, N | 1 |
| Winkels, H | 1 |
| Weber, C | 1 |
| Gieseg, SP | 1 |
| Leake, DS | 1 |
| Flavall, EM | 1 |
| Amit, Z | 1 |
| Reid, L | 1 |
| Yang, YT | 1 |
| Pawlak, K | 1 |
| Kowalewska, A | 1 |
| Mysliwiec, M | 1 |
| Pawlak, D | 1 |
| Zhang, L | 1 |
| Ovchinnikova, O | 1 |
| Jönsson, A | 1 |
| Lundberg, AM | 1 |
| Ketelhuth, DF | 1 |
| Pae, HO | 1 |
| Oh, GS | 1 |
| Lee, BS | 1 |
| Rim, JS | 1 |
| Kim, YM | 1 |
| Chung, HT | 1 |
1 review available for 3-hydroxyanthranilic acid and Atherogenesis
| Article | Year |
|---|---|
Macrophage antioxidant protection within atherosclerotic plaques.
Topics: 3-Hydroxyanthranilic Acid; Antioxidants; Ascorbic Acid; Atherosclerosis; Cell Death; Glutathione; Hu | 2009 |
5 other studies available for 3-hydroxyanthranilic acid and Atherogenesis